HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitorsA. Gabrielle J. van der Kraan, Julian M.W. Quinn, Ryan C. Chai et al.|Biochemical Journal|2013Cited by 63
Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritisRan Gu, Eric F. Morand, Günter Fingerle‐Rowson et al.|Cytokine|2015Cited by 52
Membrane-bound receptor activator of NFκB ligand (RANKL) activity displayed by osteoblasts is differentially regulated by osteolytic factorsPreetinder P. Singh, J Quinn, A. Gabrielle J. van der Kraan et al.|Biochemical and Biophysical Research Communications|2012Cited by 32
Osteoclast formation elicited by interleukin-33 stimulation is dependent upon the type of osteoclast progenitorDamien G. Eeles, J Quinn, Jason M. Hodge et al.|Molecular and Cellular Endocrinology|2014Cited by 23
Abstract 2933: HSP90 inhibiting anti-cancer therapeutics enhance bone loss by increasing osteoclast formation: Mechanism of action.A. Gabrielle J. van der Kraan, John T. Price, Matthew T. Gillespie et al.|Cancer Research|2013Cited by 0